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Abstract 
Background:  Intimate partner violence (IPV) is a serious public health problem, impacting more than 12 million people in the United 
States each year.  The only know effective health care intervention is routine screening for IPV exposure; however, this intervention 
has been poorly adopted.  Expansion of screening efforts to the community pharmacy setting provides an opportunity to have a 
substantial impact on the health and well-being of pharmacy patients.  However, little is known about pharmacists’ knowledge, 
attitudes, and behaviors related to IPV. 
Objective:  The objective of this study was to conduct an exploratory investigation of community pharmacists’ current level of 
knowledge, attitudes, behaviors, and intentions related to IPV and to IPV screening.   
Methods:  A cross-sectional study using an online questionnaire was conducted.  Surveys were distributed via email.  Descriptive 
analyses of survey responses were conducted. 
Results:  A total of 144 community pharmacists completed the survey.  Results indicated most (67.4%) had no IPV education/training.  
Participants were significantly more willing to conduct screening with targeted patients compared to all patients. (X
2
=129.62; df=36; 
p<0.0001).  There was strong agreement with interest in and willingness to participate in continuing education.         
Conclusions:  Most respondents indicated relatively low levels of IPV knowledge and training and very little current IPV screening 
activity.  Continuing education on IPV should be considered for pharmacists to increase knowledge and awareness of IPV. 
 
 
Introduction   
Intimate partner violence (IPV), also known as domestic 
violence, is a public health problem impacting more than 12 
million people in the United States each year.
1
  According to 
the National Intimate Partner and Sexual Violence Survey, 
35.6% of women and 28.5% of men are physically assaulted, 
sexually assaulted, or stalked by an intimate partner in their 
lifetime.
1
  Intimate partner violence negatively impacts health 
and well-being by causing injury or worsening health 
conditions.  Physical injuries can range from cuts and bruises 
to injuries such as broken bones, brain injuries, and even 
death.
2
  Victims of IPV experience exacerbation of chronic 
diseases due to stress and poor health behaviors, report pain 
more frequently, and use prescription pain medications more 
than those not exposed to IPV. 
3-5
 
6
  Women exposed to IPV 
have greater health care utilization and health care costs, 
incurring costs approximately 60% higher than women not 
experiencing abuse, including 27% higher pharmacy costs per 
year.
7;8
  According to the Centers for Disease Control and 
Prevention (CDC), IPV cost $8.3 billion annually when the  
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economic impact was last updated in 2003.
9
  The harm of IPV 
extends beyond the immediate victim.  Children of mothers 
exposed to IPV have increased health care utilization and 
costs,
10
 and are at a greatly increased risk for child abuse. 
11;12
  
For these reasons, IPV reduction remains a key Healthy 
People 2020 goal.
13
 
 
The health care system is actively engaged in intervening to 
decrease the impact of IPV-related injuries by providing 
medical treatment for injuries.  However, care of this nature 
is an intervention that only addresses the physical injuries 
and does not serve as a preventive measure to lessen the 
future impact of violence.  Efforts to prevent IPV and to 
reduce the impact of IPV require intervention of a different 
nature.  Screening for IPV has been proposed as the most 
effective method to prevent and reduce the impact of IPV in 
the future.
14
  Screening, identifying, and referring patients 
exposed to IPV presents an opportunity to prevent further 
physical injuries and to positively impact both the physical 
and mental health of patients.  Routine and regular 
screenings by skilled health care providers has been shown to 
significantly increase the identification of IPV 
15-17
 and is 
recommended or included as a treatment guideline by most 
health care provider groups.
18-22
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To date, pharmacists have not been involved in the effort to 
address IPV.  This is unfortunate as community pharmacists 
are both accessible and trusted members of the health care 
team.
23
  Extending IPV screening to the community pharmacy 
environment offers the potential for a significant expansion 
of this effort that may have a significant impact on IPV in the 
U.S.  However, a thorough literature review indicates that 
there has been little investigation of this clinical topic.  
Understanding community pharmacists’ knowledge and 
attitudes related to IPV and IPV screening in their practice is 
critical before developing any educational or training 
activities that would facilitate conducting IPV in the 
community pharmacy environment.   
 
Objectives 
The objective of this study was to conduct an exploratory 
investigation of community pharmacists’ current level of 
knowledge, attitudes, behaviors, and intentions related to IPV 
and to IPV screening.  The end goal is to determine if 
community pharmacies could be an accessible, reliable 
location to conduct IPV screening. 
 
Methods 
Study Design and Sample 
A cross-sectional survey design was utilized for this 
investigation.  The sampling frame was an electronic list of 
6,000 practicing community pharmacists across the U.S. 
purchased from Integrated Medical Data.  An online 
questionnaire was sent via email in Spring 2012 to these 
pharmacists using the Qualtrics software program (Qualtrics, 
Inc., Provo, UT).  An email describing the purpose of the study 
and inviting participation was sent to the pharmacists.  
Respondents were provided a $10 gift certificate for 
participation.  Participant incentives were funded via internal 
research support.  To maximize response the Dillman method 
was utilized and up to 4 reminder emails were sent to non-
responders.
24
  The study was approved by the University of 
Mississippi’s Institutional Review Board. 
 
Study Questionnaire 
The survey instrument utilized in this investigation was 
adapted from the Physician Readiness to Manage Intimate 
Partner Violence Survey (PREMIS).  This instrument was 
originally developed to assess physicians’ knowledge, 
attitudes, and beliefs regarding IPV using current IPV 
literature as the standard and to assess self-reported practice 
behaviors related to IPV.
25
  PREMIS has previously been used 
in studies of physicians and health care students (medicine, 
dentistry, nursing, and social work) and has been found to be 
comprehensible, reliable, valid, and adaptable to health care 
providers beyond physicians.
25-27
  The current study was part 
of a validation study of an adaptation of the PREMIS 
instrument specifically for pharmacy practice.   These 
adaptations were made to address the unique practice 
characteristics, activities, and concerns of a community 
pharmacy practitioner.  The study survey is included as 
Appendix 1. 
 
Data Analysis 
Descriptive analysis of respondents’ demographic, training 
and practice characteristics, and items assessing knowledge, 
attitudes, behaviors, and intentions related to IPV and IPV 
screening was performed.  Means and standard deviations 
were calculated for continuous items and frequencies and 
proportions were calculated for categorical items.  Analyses 
were conducted utilizing Statistical Package for Social 
Sciences Version 20.0 (SPSS, Inc., Chicago, IL).   
 
Results 
Demographic and Practice Characteristics 
A total of 189 pharmacists responded; however, 45 of these 
were not included in the final sample as they had more than 
20% missing data, resulting in a final sample of 144 
participants.  Potential non-response bias was assessed by 
comparing study respondents to the population values of the 
population from which the study sample was drawn on 
pharmacy type and position in the pharmacy and no 
significant differences between the groups were found.   
Further, a time trends extrapolation comparing the first 20% 
(n=29) of respondents to the last 20% (n=29) of respondents 
was conducted utilizing Student’s t-tests and Chi-square tests 
to determine if differences in demographic and practice 
variables existed between these two groups.  No significant 
differences between the groups were found.  
 
The mean age of participants was 47.9 years (±11.8 years). 
The demographic and pharmacy training characteristics of the 
study sample are listed in Table 1.  Examination of the 
practice characteristics of the study participants indicates 
that they work in a variety of types of pharmacies and hold a 
variety of positions.  Interestingly, approximately half of the 
study sample reported working in a pharmacy that offers 
advanced pharmacy services such as MTM, diabetes 
education, and asthma management.  As anticipated given 
the reported level of advanced pharmacy services offered, 
57.6% reported that their pharmacy had a private counseling 
area, with 34.9% reporting that this area is used often.  Daily 
fill rates and other practice characteristics are included in 
Table 2. 
 
Knowledge and Attitudes 
Community pharmacists’ exposure to IPV training is included 
in Table 3.  Overall, participating pharmacists reported little 
exposure to IPV-related training, with the majority (67.4%) 
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reporting no training at all.  The PREMIS instrument includes 
questions to assess both actual and perceived knowledge 
about IPV and perceived preparation to manage IPV.  The 
mean score on the actual knowledge scale in this sample of 
pharmacists was 20.83±6.04, lower than the reported scale 
mean in a sample of physicians (26.0±5.18) and a sample of 
health care students (23.9±5.68). 
25;26
  Most pharmacy 
participants were uncertain if there is a legal mandate to 
report IPV cases involving competent adults in the state in 
which they practice (77.6% reported “Unsure”).  Pharmacists 
also reported low levels of perceived preparedness and 
perceived knowledge related to IPV screening (Table 4).  
These perceptions had an impact on both self-efficacy and 
workplace-efficacy related to IPV screening, with participants 
reporting low levels of both, as well as indicating concern 
about constraints related to time and training for IPV 
screening.   
 
Behaviors and Intentions 
Participants reported minimal identification of IPV cases in 
their clinical practice.  When asked “How many new cases 
would you estimate you have identified in the past six 
months?”, only 3 participants (2.2%) reported identifying a 
case.  Six respondents (4.2%) reported screening patients 
with abuse indicators.  Three respondents (2.1%) reported 
screening patients periodically and 4 (2.8%) reported 
screening all female patients periodically.  For respondents 
who identified a case, the most common actions were to 
refer the patient to other assistance, to provide information, 
and to counsel the patient about options she/he may have.  
Participants responded to 3 items related to intention to 
participate in continuing education and screening for IPV on a 
scale of 1 (strongly disagree) to 7 (strongly agree).  
Respondents endorsed intention to participate in continuing 
education (Table 5).  There was a significant difference 
between intentions to conduct screening with all patients 
compared to targeted patients, with respondents more 
willing to conduct screening with targeted patients 
(X
2
=129.62; df=36; p<0.0001).           
 
Two open-ended questions regarding IPV and community 
pharmacies were included in the survey.  Several pharmacists 
noted their lack of training.  One pharmacist responded, “I 
feel that pharmacists are not trained in this area but we 
should be.”  Others indicated screening could be possible and 
valuable in the community pharmacy environment.  For 
example, one reported “If we have referral sites (which we do 
in our community) these screenings could be done at the 
pharmacy level.”  Another indicated IPV screening “would be 
a useful resource.”   Other response themes included 
concerns regarding time and acceptability.   
 
Discussion 
Intimate partner violence is one of the most highly prevalent 
health threats in the U.S. population.  The only known health 
system intervention that has the possibility to reduce and 
prevent negative health outcomes from IPV is routine 
screening for IPV exposure.  Community pharmacists are 
uniquely positioned to conduct screening as they are highly 
accessible, with patients often having repetitive exposure to 
the pharmacists, in an environment in which patients are 
already receiving health-related educational information.  To 
the best of our knowledge, this is the first study to assess 
pharmacists’ training, knowledge, and practice activities 
related to IPV. 
 
The data from this investigation indicate that there is minimal 
awareness, knowledge, training, and skills related to IPV and 
IPV screening in community pharmacists, despite patients’ 
easy access to these health care providers.  These findings are 
not surprising given the reported lack of training or education 
related to this topic.  This translates into nearly no reported 
screening, identification, nor referrals related to IPV in their 
practices.  Given the significant health impact of IPV and the 
relevant impact IPV has on medication usage patterns, this is 
a clinical opportunity to improve pharmacy provision of 
patient care.  Initial efforts should be targeted at the 
predisposing factors related to IPV screening in the 
community pharmacy environment.  Given the minimal level 
of awareness of IPV, priority should be placed on developing 
continuing education programs to inform practicing 
pharmacists of the prevalence of this health threat and 
increase awareness of the value of routine screening.  A 
similar initiative in curricula in pharmacy training programs 
should immediately be considered as well.  In fact, there is 
likely significant demand for education on this issue.  The 
respondents in this survey indicated that they would enroll in 
continuing education about IPV [mean =5.15 ±1.79; scale 1 
(strongly disagree) to 7 (strongly agree)], with the largest 
response, 27.5%, endorsing strongly agree.  The next steps 
would be to further evaluate the potential barriers in the 
pharmacy setting, particularly at the consumer level, and to 
develop educational and training programs to prepare 
pharmacists to engage in screening.    
 
Limitations 
There are several limitations to this investigation.  First, 
participants responded to a survey on what they may 
consider a sensitive issue.  It is possible that their discomfort 
with this topic may have impacted their responses.  Second, 
based on a review of the literature and the results of this 
investigation it is clear that community pharmacists have had 
little formal education or exposure to issues related to 
intimate partner violence.  With more education, opinions 
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and perspectives may change and as a result responses to 
many of the survey items may be impacted by this lack of 
knowledge and awareness.  Finally, while this study had more 
subjects than the prior investigations in other health care 
practitioner groups with this instrument, the generalizability 
of the results of this study are limited by the relatively small 
sample size due to a low response rate.   
 
There are several potential reasons for the low response rate.  
First, this study was conducted as part of a larger survey 
validation project and the survey time burden was quite 
substantial and may have impacted participation rates.  
Second, email surveys have been found to have lower 
response rates compared to postal surveys.
28
  Third, the topic 
of this survey is out of the traditional practice realm for 
community pharmacists and is of a sensitive nature.  These 
factors combined may have made the survey less interesting 
to pharmacists.  Finally, this study utilized a national sample 
in order to avoid regional differences in practice and attitudes 
related to IPV.  However, pharmacists likely felt no 
relationship with the investigators as the study was not from 
a practice group or national association, reducing the interest 
in completing the study.  An analysis of early and late 
responders was completed to attempt to ascertain potential 
non-response bias and no difference between these groups 
was identified, indicating a reduced chance of non-response 
bias.   
 
Conclusion  
Intimate partner violence is a highly prevalent, serious health 
threat that is amenable to prevention efforts through routine 
screening programs.  While respondents expressed concern 
regarding IPV training and time burden for IPV screening, 
they indicated that participation in screening may be valuable 
to patient health and offer a relative advantage for their 
pharmacies.  Interestingly, female pharmacists were more 
likely to report intent to screen targeted patients for IPV.   
There was strong support for continuing education related to 
IPV in pharmacy practice.  Continuing education would be an 
important first step in facilitating community pharmacists’ 
understanding of an important factor influencing patients’ 
medication consumption and would be needed prior to the 
development of IPV screening programs in the community 
pharmacy environment.  As solutions are sought to reduce 
the rates and impact of IPV in the U.S., policy makers and 
victim advocacy groups should consider pharmacists as 
potential care partners to address this highly prevalent health 
problem. 
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Table 1. Participant Characteristics 
        Percent  n 
Sex 
 Female       52.8%  76 
 Male       47.2%  68 
Race 
 White       84.7%  122   
 Black/African American     3.5%  5 
 Asian       7.6%  11 
 Native Hawaiian/Pacific Islander    0.7%  1 
 American Indian/Alaskan Native    0.7%  1 
 Other       2.8%  4 
Hispanic  
 Yes       5.6%  8 
 No       93.8%  135 
 Don’t know/Not sure     0.7%  1 
Most advanced pharmacy training 
 B.S. in Pharmacy      59.7%  86 
 Pharm.D.      37.5%  54 
 M.S. in Pharmacy      2.1%  3 
 Other       0.7%  1 
Postgraduate training  
 Residency      16.0%  23   
 Fellowship      2.8%  4 
 Graduate School      19.4%  28 
 Other       31.9%  46 
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Table 2. Practice Characteristics 
        Percent  n 
Type of pharmacy 
 Chain       11.8%  17 
 Grocery/General Merchandise    28.5%  41 
 Independent      34.0%  49 
 Other       32.6%  47 
Position  
 Owner/Partner      18.1%  26 
 Employee manager/Asst Manager    27.8%  40 
 Staff/employee pharmacist    47.2%  68 
 Relief pharmacist      2.1%  3 
 Other       4.9%  7 
Extent involved in key decisions 
 Not at all      15.3%  22 
 A little       17.4%  25 
Some       16.0%  23 
A good amount      27.1%  39 
To a great extent      24.3%  35 
Offer advanced pharmacy services 
 YES       53.5%  77 
 NO       46.5%  67 
Have a dedicated private counseling area 
 YES       57.6%  83 
 NO       42.4%  61    
Frequency of use of private counseling area 
 Never       --  0 
 Rarely       13.3%  11 
 Sometimes       51.8%  43 
 Often       34.9%  29 
        Mean (±SD) 
Average number of fills per day in your pharmacy   326.3 (±674.3) 
Percent of fills involving patient counseling other than   
 ordinary prescription consultation    22.7% (±26.3) 
Average number of pharmacist FTEs in your pharmacy  5.76 (±17.1) 
Average number of pharmacy tech FTEs in your pharmacy  7.58 (±26.8) 
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Table 3. Pharmacist Intimate Partner Violence Training Activities 
       Percent  n Mean (SD) 
None       67.4%  97 
Read institution’s protocol    13.2%  19 
Watched a video      11.1%  16 
Attended lecture/talk     9.0%  13 
Attended skills based training/workshop   2.8%  4 
Pharmacy/other school classroom workshop  2.8%  4 
Pharmacy/other school clinical training   2.8%  4  
Residency/fellowship/post-grad training   --  0 
Continuing Education     8.3%  12 
Other       2.1%  3 
Total hours of training        5.5 (7.1) 
 
 
 
 
 
 
Table 4. Pharmacist PREMIS Scales  
 
Scale Alpha Total 
Items 
Item Mean (SD)* Sample Item 
Actual Knowledge n/a 18 20.83 (6.04) What is the strongest single risk factor for being a victim of 
intimate partner violence? 
Perceived Knowledge 0.978 16 2.21 (0.004) How much do you feel you know about what questions to 
ask to identify IPV? 
Perceived 
Preparation 
0.970 12 2.31 (0.003) How prepared do you feel to appropriately respond to 
disclosures of abuse? 
Efficacy – 
Workplace/Self 
0.856 7 2.68 (0.013) I feel comfortable discussing IPV with my patients. 
My practice setting allows me adequate time to respond to 
victims of IPV. 
*On a scale from 1 (strongly disagree) to 7 (strongly agree) 
 
 
 
 
 
 
Table 5. Intentions Related to Continuing Education & Screening for Intimate Partner Violence 
         Mean (SD)*   
I would enroll in continuing education about IPV.    5.15 (1.79) 
I would conduct IPV screening with all pharmacy patients.   3.34 (1.83) 
I would conduct IPV screening with targeted pharmacy patients.  4.74 (1.75)  
*On a scale from 1 (strongly disagree) to 7 (strongly agree) 
 
 
